CPC Launches Aseptic Product for Cell and Gene Therapy Cryopreservation

Rhea-AI Summary

CPC, a Dover company (NYSE: DOV), has launched the MicroCNX® ULT Series, a new aseptic micro-connector for cell and gene therapy (CGT) cryopreservation. This innovative product fits directly into freeze cassettes and withstands temperatures down to -190°C, supporting sterility throughout CGT development processes. The connectors are compatible with harsh chemicals like DMSO and common CGT tubing types.

This launch builds on CPC's earlier introduction of the 1/8" MicroCNX Series and the recent MicroCNX Luers. These products aim to provide flexible, sterile connection solutions for CGT manufacturers, from benchtop to commercialization. CPC continues to expand its aseptic connector portfolio to meet the evolving needs of the biopharma industry globally.

Positive

• Launch of MicroCNX® ULT Series, a new aseptic micro-connector for CGT cryopreservation
• Product withstands temperatures down to -190°C, supporting sterility in CGT processes
• Expansion of CPC's aseptic connector portfolio, strengthening market position
• Compatibility with harsh chemicals and common CGT tubing types
• Recent introduction of MicroCNX Luers, offering additional flexibility for manufacturers

Negative

• None.

Insights

Biotech Manufacturing Expert

The launch of CPC's MicroCNX® ULT Series represents a significant advancement in cell and gene therapy (CGT) cryopreservation. This innovative micro-connector addresses critical challenges in the CGT manufacturing process, particularly in maintaining sterility and product integrity during ultra-low temperature storage and transportation.

Key advantages include:

• Withstanding temperatures down to -190°C, surpassing typical cryopreservation requirements
• Compact design fitting into CGT freeze cassettes, enhancing practicality
• Chemical compatibility with DMSO and common CGT tubing materials

This product could potentially reduce material loss and improve the efficacy of CGT products, ultimately benefiting patient outcomes. For CPC and Dover, this innovation strengthens their market position in the rapidly growing CGT sector, potentially driving increased revenue and market share.

Medical Research Analyst

The MicroCNX® ULT Series addresses a critical need in cell and gene therapy research and development. By ensuring sterility at ultra-low temperatures, it could significantly enhance the reliability of cryopreservation processes, a important step in CGT product development and delivery.

This innovation may accelerate CGT research by:

• Reducing contamination risks during storage and transport
• Improving cell viability post-thaw, potentially leading to more consistent therapeutic outcomes
• Enabling more efficient handling of small-volume samples typical in personalized therapies

For the broader biotech industry, this advancement could contribute to faster development cycles and potentially lower costs in bringing CGT products to market, benefiting both companies and patients.

DOWNERS GROVE, Ill., Sept. 11, 2024 /PRNewswire/ -- CPC (Colder Products Company), part of Dover (NYSE: DOV) and a leading manufacturer of connection technologies used in biopharmaceutical processing, today announced the launch of a new aseptic micro-connector that fits directly into the freeze cassettes used in cell and gene therapy (CGT) processing.

Cryopreservation – freezing CGT biological materials at ultralow temperatures – helps minimize material loss of function during product shipment and storage, which occur before therapies are delivered to patients.

"To support cell health, shelf life, and transportation needs, many cell therapy processes are dropping to -150ºC or lower temperature ranges," said Troy Ostreng, Senior Product Manager for CPC's biopharmaceutical business. "The new MicroCNX^® ULT Series is the first to conveniently support sterility throughout CGT development processes by both withstanding temperatures to -190°C and being compact enough to conveniently fit into a CGT freeze cassette."

MicroCNX ULT connectors provide a simple, efficient method for sterile connection of tubing used for small-format cell therapy and gene therapy assemblies. The connectors are also chemically compatible with harsh chemicals used in cryopreservation processes like dimethyl sulfoxide (DMSO) and the most commonly used tubing types in CGT development, including polyvinyl chloride (PVC).

This new series builds on CPC's pioneering work in creating biopharma's smallest connector, the 1/8" MicroCNX Series, which is the only alternative to tube welding for creating closed sterile connections at small volumes.

In June, CPC also introduced MicroCNX Luers. Manufacturers that routinely connect with luers appreciate the flexibility this new product offers in creating sterile connections outside of a biosafety cabinet.

"As a leader in aseptic connection technologies, our goal is to scale with our customers, helping them easily create sterile connections from the benchtop to commercialization," said Ostreng. "CPC already has the broadest aseptic connector portfolio. MicroCNX ULT connectors are just one more example of our continued innovation to meet the evolving needs of cell therapy, gene therapy, and biopharma manufacturers across the globe," he added. 

For more information about the performance and versatility of the MicroCNX series connectors or any of the other innovative connection solutions CPC offers, visit cpcworldwide.com/micro.

About CPC:

CPC (Colder Products Company) is the leader in single-use connection technology, offering a wide variety of connectors for biopharmaceutical manufacturing. The company's innovative, flexible products enable users to easily combine multiple components and systems including process containers, tubing manifolds, transfer lines, bioreactors and other bioprocess equipment. Robust single-use connectors maintain media sterility and integrity while improving production yields, decreasing time to market and reducing costs. The company's well-known AseptiQuik^® connectors provide quick and easy sterile connections even in non-sterile environments. Learn more at cpcworldwide.com/bio. Connect with confidence with CPC, an operating company within Dover Corporation.

About Dover:

Dover is a diversified global manufacturer and solutions provider with annual revenue of over $8 billion. We deliver innovative equipment and components, consumable supplies, aftermarket parts, software and digital solutions, and support services through five operating segments: Engineered Products, Clean Energy & Fueling, Imaging & Identification, Pumps & Process Solutions and Climate & Sustainability Technologies. Dover combines global scale with operational agility to lead the markets we serve. Recognized for our entrepreneurial approach for over 65 years, our team of approximately 25,000 employees takes an ownership mindset, collaborating with customers to redefine what's possible. Headquartered in Downers Grove, Illinois, Dover trades on the New York Stock Exchange under "DOV." Additional information is available at dovercorporation.com.

CPC Contact:  
Jana Stender 
(612) 564-2053
jana.stender@cpcworldwide.com

Dover Media Contact:
Adrian Sakowicz, VP, Communications
(630) 743-5039
asakowicz@dovercorp.com

Dover Investor Contact:
Jack Dickens, Senior Director, Investor Relations
(630) 743-2566
jdickens@dovercorp.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cpc-launches-aseptic-product-for-cell-and-gene-therapy-cryopreservation-302245274.html

SOURCE Dover

FAQ

What is the new product launched by CPC for cell and gene therapy cryopreservation?

CPC has launched the MicroCNX® ULT Series, a new aseptic micro-connector that fits directly into freeze cassettes used in cell and gene therapy (CGT) cryopreservation processes.

What temperature range can the MicroCNX® ULT Series withstand?

The MicroCNX® ULT Series can withstand temperatures down to -190°C, supporting sterility throughout CGT development processes.

How does the MicroCNX® ULT Series benefit cell and gene therapy manufacturers?

The MicroCNX® ULT Series provides a simple, efficient method for sterile connection of tubing in small-format cell and gene therapy assemblies, supporting cell health, shelf life, and transportation needs at ultralow temperatures.

What other products has CPC recently introduced in its aseptic connector portfolio?

CPC recently introduced MicroCNX Luers, which offer flexibility in creating sterile connections outside of a biosafety cabinet for manufacturers that routinely connect with luers.